{"id":"W2792282698","doi":"10.1158/1538-7445.sabcs17-p5-21-03","title":"Abstract P5-21-03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"","keywords":"Palbociclib; Medicine; Internal medicine; Population; Progression-free survival; Breast cancer; Estrogen receptor; Metastatic breast cancer; Letrozole; Clinical endpoint; Cancer; Gynecology; Gastroenterology; Oncology; Randomized controlled trial; Overall survival; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006978124,0.0008749859,0.001193898,0.0003680819,0.00101844,0.0001479999,0.0005119735,0.0003360303,0.004848264],"category_scores_gemma":[0.0002020936,0.0006998837,0.000175165,0.001365291,0.002325006,0.000841472,0.0002861609,0.001610183,0.0001554827],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002193628,"about_ca_system_score_gemma":0.0007676685,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006925947,"about_ca_topic_score_gemma":0.003939147,"domain_scores_codex":[0.9933333,0.0003802113,0.0009156552,0.00168469,0.001561981,0.002124111],"domain_scores_gemma":[0.9953036,0.0007230273,0.0004019609,0.0008222758,0.001975034,0.0007740977],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1198794,0.001725895,0.1954643,0.000540608,0.002176757,0.0002282387,0.04178298,0.000138982,0.1646355,0.0002134521,0.001225182,0.4719886],"study_design_scores_gemma":[0.03774436,0.006615875,0.660306,0.002827488,0.00006330737,0.00009291471,0.00439642,0.00001887077,0.2742376,0.0002749441,0.0118733,0.001548849],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854237,0.00457476,0.00003019599,0.004558919,0.0003404313,0.003067706,0.001575787,0.0001451854,0.0002832717],"genre_scores_gemma":[0.9909325,0.004651735,0.0004165967,0.0006146188,0.001042936,0.001294809,0.0002049803,0.0002627839,0.000579019],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4704398,"threshold_uncertainty_score":0.999687,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03254231058613841,"score_gpt":0.3694373333917152,"score_spread":0.3368950228055768,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}